Sector: Healthcare
BR_HAPV
Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.
Shares: yahoo_fundamentals_timeseries/HAPV3.SA
Monetary columns are in M USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.
| Date | Period | Status | RevenueM USD | Operating profitM USD | D&AM USD | EBITDAM USD | Net profitM USD | Operating CFM USD | Capex + M&AM USD | AssetsM USD | EquityM USD | ROE (annualized) | Net debtM USD | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Q2 2026 (3M) | PARTIAL | 240.0 y/y 55.1% | -33.7 y/y 179.3% | 63.4 y/y -14.4% | 136.2 y/y 36.0% | 5.1 y/y — | -57.1 | 4.0 | 14336.0 y/y 7.5% | 9464.9 y/y 8.6% | -0.6% | 989.4 | Link |
| 2026-03-31 | Q1 2026 (3M) | PARTIAL | 277.4 y/y 6.1% | 106.5 y/y -10.8% | 64.2 y/y -15.7% | 170.7 y/y -12.7% | -20.1 y/y -160.7% | 124.8 | -38.0 | 14546.7 y/y 10.1% | 9597.2 y/y 10.4% | -0.9% | 991.2 | Link |
| 2025-12-31 | FY 2025 (12M) | PARTIAL | — y/y 23.2% | 55.3 y/y 60.9% | 59.0 y/y 27.9% | 114.3 y/y 42.0% | -15.8 y/y 54.6% | 52.8 | -77.6 | 13200.7 y/y 11.0% | 8810.9 y/y 11.8% | -0.3% | 913.9 | Link |
| 2025-09-30 | Q3 2025 (3M) | PARTIAL | 1471.2 y/y 9.6% | 65.2 y/y 48.6% | 76.0 y/y 1.2% | 141.3 y/y 18.7% | 75.6 y/y — | 51.8 | -41.8 | 13836.7 y/y 7.9% | 9039.8 y/y 7.0% | 0.2% | 715.7 | Link |
| 2025-06-30 | Q2 2025 (3M) | PARTIAL | 154.7 y/y 98.6% | 26.1 y/y — | 74.1 y/y -1.2% | 100.2 y/y 423.4% | -92.5 y/y — | 114.7 | -35.4 | 13335.6 y/y 0.9% | 8712.5 y/y 0.3% | -2.7% | 633.7 | Link |
| 2025-03-31 | Q1 2025 (3M) | PARTIAL | 261.4 y/y 1.2% | 119.4 y/y 22.4% | 76.2 y/y -6.8% | 195.6 y/y 9.1% | 33.1 y/y 185.9% | 157.5 | -35.3 | 13206.7 y/y -7.1% | 8695.0 y/y -9.5% | 1.6% | 652.4 | Link |
| 2024-12-31 | FY 2024 (12M) | PARTIAL | — y/y -18.4% | 34.4 y/y -75.7% | 46.1 y/y -49.8% | 80.5 y/y -65.5% | -34.7 y/y -21.0% | 43.0 | -45.7 | 11897.2 y/y -21.3% | 7879.2 y/y -22.6% | -1.3% | 644.3 | Link |
| 2024-09-30 | Q3 2024 (3M) | PARTIAL | 1342.1 y/y 458.5% | 99.8 y/y -30.7% | 75.1 y/y -8.6% | 119.0 y/y -18.2% | 53.7 y/y — | 125.6 | -31.4 | 12818.9 y/y -11.3% | 8449.9 y/y -13.7% | -0.2% | 636.6 | Link |
| 2024-06-30 | Q2 2024 (3M) | PARTIAL | 77.9 y/y -94.6% | -153.4 y/y -420.8% | 75.0 y/y -13.0% | 19.1 y/y -81.5% | -79.4 y/y — | 92.0 | -33.0 | 13223.0 y/y -14.9% | 8689.4 y/y -17.1% | -3.0% | 707.5 | Link |
| 2024-03-31 | Q1 2024 (3M) | PARTIAL | 258.2 y/y 15.4% | 97.5 y/y 386.0% | 81.7 y/y 8.0% | 179.2 y/y 87.2% | 11.6 y/y — | 180.7 | -20.5 | 14223.1 y/y -1.6% | 9610.1 y/y -1.7% | 0.5% | 779.9 | Link |
| 2023-12-31 | FY 2023 (12M) | PARTIAL | — y/y — | 141.3 y/y — | 91.9 y/y — | 233.2 y/y — | -28.7 y/y — | 117.5 | -15.8 | 15124.4 y/y — | 10178.9 y/y — | -1.6% | 934.7 | Link |
| 2023-09-30 | Q3 2023 (3M) | PARTIAL | 240.3 y/y — | 63.3 y/y — | 82.2 y/y — | 145.5 y/y — | -19.5 y/y — | 156.1 | -20.1 | 14445.5 y/y — | 9787.7 y/y — | -0.3% | 1085.6 | Link |
| 2023-06-30 | Q2 2023 (3M) | PARTIAL | 1439.8 y/y — | 17.4 y/y — | 86.2 y/y — | 103.6 y/y — | -60.7 y/y — | 73.6 | -25.8 | 15530.0 y/y — | 10479.7 y/y — | -2.4% | 1238.2 | Link |
| 2023-03-31 | Q1 2023 (3M) | PARTIAL | 223.7 y/y — | 20.1 y/y — | 75.7 y/y — | 95.7 y/y — | -47.6 y/y — | 135.3 | -23.4 | 14452.6 y/y — | 9778.6 y/y — | — | 1488.3 | Link |
Quarterly values ($ mln)
Year-over-year change
FCF ($ mln)
Net debt / cash ($ mln)
Our earnings breakdowns and investment notes on this issuer.
Value the company creates per year, as a % of market cap
Value created per year: -47.5%
| 1. EBITDA growth (latest quarter YoY, annualised) [EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-06-30 vs 2025-06-30) = (136 − 100) × 4.13 | 13 |
| 2. Current EV/EBITDA (LTM) (Market cap + Net debt) ÷ EBITDA (LTM) = (611 + 989) ÷ 562 | 2.8x |
| 3. Target multiple (Current EV/EBITDA + 7) ÷ 2 = (2.8 + 7) ÷ 2 | 4.9x |
| 4. Cash flow (balance method, LTM) Net-debt reduction + dividends + buybacks − equity issuance = -356 + 0 + 0 − 0 | -356 |
| 5. Value created per year (EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap = (13 × 4.9 + -356) ÷ 611 | -47.5% |
Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.
Caveats:
Group: Healthcare. Each peer is shown as it trades and re-priced onto this company's market (Brazil) by the ratio of our coverage medians.
| Company | Market | Cap, $bn | EV/EBITDA | EV/EBITDA, adjusted |
|---|---|---|---|---|
| UNITEDHEALTH GROUP INC | US | 340.5 | 14.6x | 4.4x |
| Merck & Co., Inc. | US | 360.5 | 15.1x | 4.6x |
| AMGEN INC | US | 202.4 | 15.3x | 4.6x |
| JOHNSON & JOHNSON | US | 643.4 | 20.1x | 6.1x |
| Netcare | South Africa | 1.3 | 5.0x | 6.6x |
| AbbVie Inc. | US | 465.6 | 22.7x | 6.8x |
| Life Healthcare | South Africa | 1.0 | 5.5x | 7.3x |
| THERMO FISHER SCIENTIFIC INC. | US | 241.3 | 25.2x | 7.6x |
| ELI LILLY & Co | US | 1023.2 | 30.0x | 9.0x |
| Promomed | Russia | 1.2 | 6.3x | 11.3x |
| MD Medical | Russia | 1.4 | 7.4x | 13.2x |
| Mitra Keluarga Karyasehat | Indonesia | 1.4 | 12.1x | 21.2x |
| Group median | 14.9x | 7.1x | ||
| Group average | 14.9x | 8.6x | ||
| This company | Brazil | 0.6 | 2.8x | 2.8x |
Group median 14.9x as traded, 7.1x adjusted; this company 2.8x — a 60% discount.
Group average 14.9x as traded, 8.6x adjusted; against the average this company is at a 67% discount.
The gap and the implied upside are measured against the median: one richly priced peer moves an average, not a median. The market adjustment uses our coverage medians (US 23.2x, Russia 3.9x, South Africa 5.3x, Kazakhstan 5.0x, India 18.0x, Indonesia 4.0x); it is about where a name is listed, not what it does. Peer multiples come from the nightly rebuild of 2026-09-16; the company's own is live.
| Date | Per share | Details | Status | Source |
|---|---|---|---|---|
| 2021-12-28 | 0.0806 BRL | Ex-dividend: 0.0806 BRL per share | Paid | Yahoo Finance (ex-div) |
| 2021-09-28 | 0.1765 BRL | Ex-dividend: 0.1765 BRL per share | Paid | Yahoo Finance (ex-div) |
KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).
Investor reporting (IR): https://www.rad.cvm.gov.br/ENET/frmConsultaExternaCVM.aspx?codigoCVM=24392
Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)
Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Hapvida — from primary filings.
See also: The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map